Unicancer
François-Clément Bidard is an experienced medical professional specializing in breast cancer, currently serving as the Medical Coordinator for Breast Cancer at Institut des Cancers des Femmes and as the Vice Chair of the Breast Cancer Group at Unicancer. Since September 2017, François-Clément has held the position of Professor of Medicine at Université de Versailles Saint-Quentin-en-Yvelines, and has been a Medical Oncologist at Institut Curie - Ensemble hospitalier since January 2014. François-Clément has also contributed to breast cancer research as a Visiting Investigator at Memorial Sloan Kettering Cancer Center and as an Assistant Medical Oncologist at Institut Curie - Research Centre. Educational qualifications include a Master of Science in Cell Biology from Ecole normale supérieure, an MD in Medical Oncology from Pierre and Marie Curie University, a PhD in Cellular and Molecular Biology from Paris-Sud University, and a Baccalauréat from Lycée Henri IV.
This person is not in any teams
Unicancer
UNICANCER groups together the 20 French Comprehensive Cancer Centres (FCCCs) which are private, not-for-profit hospitals located across the French territory. FCCCs are dedicated to fighting cancer through a threefold mission of patient care, research and education. They contribute to the public hospital service in accordance with statutory fees, with no additional charge. UNICANCER is one of the largest cancer care and research organisations in Europe. Via its R&D department, it sponsors clinical trials to improve cancer patients’ care and access to innovation, particularly in areas neglected by the pharmaceutical industry. UNICANCER is accredited by the French Ministry of Health and is eligible for public grants. The French Comprehensive Cancer Centres in numbers: • 20 sites located throughout the French territory • 19,000 employees • >135,000 patients hospitalised each year • Approximately 500 active clinical trials • 17% of the patients treated are included in a clinical trial (vs an average of 8.5% of cancer patients in France) • 19 molecular biology platforms certified by the French National Cancer Institute • 7 integrated cancerology research sites (SIRIC) certified by the French NCI (out of 8) • 12 early-phase clinical trial Centres (CLIP²) certified by the French NCI (out of 16) • 5th for global publications in oncology • 32% of French publications in oncology (articles in which FCCCs have participated) UNICANCER sponsors • 76 ongoing clinical trials (2016) • Including 5400 patients (2016) • From 270 investigator sites (2015), • With 20% located in other European countries